Your browser doesn't support javascript.
loading
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
Yacoub, Abdulraheem; Mascarenhas, John; Kosiorek, Heidi; Prchal, Josef T; Berenzon, Dmitry; Baer, Maria R; Ritchie, Ellen; Silver, Richard T; Kessler, Craig; Winton, Elliott; Finazzi, Maria Chiara; Rambaldi, Alessandro; Vannucchi, Alessandro M; Leibowitz, David; Rondelli, Damiano; Arcasoy, Murat O; Catchatourian, Rosalind; Vadakara, Joseph; Rosti, Vittorio; Hexner, Elizabeth; Kremyanskaya, Marina; Sandy, Lonette; Tripodi, Joseph; Najfeld, Vesna; Farnoud, Noushin; Papaemmanuil, Elli; Salama, Mohamed; Singer-Weinberg, Rona; Rampal, Raajit; Goldberg, Judith D; Barbui, Tiziano; Mesa, Ruben; Dueck, Amylou C; Hoffman, Ronald.
Afiliación
  • Yacoub A; Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Westwood, KS.
  • Mascarenhas J; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Kosiorek H; Mayo Clinic, Scottsdale, AZ.
  • Prchal JT; Division of Hematology, University of Utah School of Medicine and.
  • Berenzon D; Huntsman Cancer Center, Salt Lake City, UT.
  • Baer MR; Comprehensive Cancer Center, Wake Forest University Medical Center, Wake Forest Health, Winston-Salem, NC.
  • Ritchie E; Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD.
  • Silver RT; Division of Hematology and Oncology, Department of Medicine, Richard T. Silver Myeloproliferative Neoplasms Center, Weill Cornell Medical College, New York, NY.
  • Kessler C; Division of Hematology and Oncology, Department of Medicine, Richard T. Silver Myeloproliferative Neoplasms Center, Weill Cornell Medical College, New York, NY.
  • Winton E; Georgetown University Medical Center, Washington, DC.
  • Finazzi MC; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA.
  • Rambaldi A; Department of Hematology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
  • Vannucchi AM; Department of Hematology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
  • Leibowitz D; Department of Oncology, University of Milan, Ospedale Papa Giovanni XXIII, Bergamo, Italy.
  • Rondelli D; Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, and.
  • Arcasoy MO; Denothe Excellence Center, University of Florence, Florence, Italy.
  • Catchatourian R; Department of Oncology, Palo Alto Medical Foundation, Sutter Health, Palo Alto, CA.
  • Vadakara J; Division of Hematology and Oncology, University of Illinois, Chicago, IL.
  • Rosti V; Division of Hematology, Duke University School of Medicine, Durham, NC.
  • Hexner E; Department of Oncology, John H. Stroger Jr. Hospital of Cook County, Chicago, IL.
  • Kremyanskaya M; Geisinger Medical Center, Danville, PA.
  • Sandy L; Laboratory of Biochemistry, Biotechnology, and Advanced Diagnosis, Center for the Study of Myelofibrosis, Istituto Di Ricovero e Cura a Carattere Scientifico, Foundation Policlinico San Matteo, Pavia, Italy.
  • Tripodi J; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
  • Najfeld V; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Farnoud N; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Papaemmanuil E; Department of Pathology and.
  • Salama M; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Singer-Weinberg R; Department of Pathology and.
  • Rampal R; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Goldberg JD; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Barbui T; Computational Oncology.
  • Mesa R; Center for Hematological Malignancies, and.
  • Dueck AC; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Hoffman R; Mayo Clinic Laboratories, Rochester, MN.
Blood ; 134(18): 1498-1509, 2019 10 31.
Article en En | MEDLINE | ID: mdl-31515250
Prior studies have reported high response rates with recombinant interferon-α (rIFN-α) therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV). To further define the role of rIFN-α, we investigated the outcomes of pegylated-rIFN-α2a (PEG) therapy in ET and PV patients previously treated with hydroxyurea (HU). The Myeloproliferative Disorders Research Consortium (MPD-RC)-111 study was an investigator-initiated, international, multicenter, phase 2 trial evaluating the ability of PEG therapy to induce complete (CR) and partial (PR) hematologic responses in patients with high-risk ET or PV who were either refractory or intolerant to HU. The study included 65 patients with ET and 50 patients with PV. The overall response rates (ORRs; CR/PR) at 12 months were 69.2% (43.1% and 26.2%) in ET patients and 60% (22% and 38%) in PV patients. CR rates were higher in CALR-mutated ET patients (56.5% vs 28.0%; P = .01), compared with those in subjects lacking a CALR mutation. The median absolute reduction in JAK2V617F variant allele fraction was -6% (range, -84% to 47%) in patients achieving a CR vs +4% (range, -18% to 56%) in patients with PR or nonresponse (NR). Therapy was associated with a significant rate of adverse events (AEs); most were manageable, and PEG discontinuation related to AEs occurred in only 13.9% of subjects. We conclude that PEG is an effective therapy for patients with ET or PV who were previously refractory and/or intolerant of HU. This trial was registered at www.clinicaltrials.gov as #NCT01259856.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Policitemia Vera / Polietilenglicoles / Interferón-alfa / Trombocitemia Esencial / Antineoplásicos Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Año: 2019 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Policitemia Vera / Polietilenglicoles / Interferón-alfa / Trombocitemia Esencial / Antineoplásicos Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Año: 2019 Tipo del documento: Article